25 XP   0   0   10

Samsung Pharm
Buy, Hold or Sell?

Let's analyse Samsung Pharm together

PenkeI guess you are interested in Samsung Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Samsung Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Samsung Pharm

I send you an email if I find something interesting about Samsung Pharm.

Quick analysis of Samsung Pharm (30 sec.)










What can you expect buying and holding a share of Samsung Pharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩824.31
Expected worth in 1 year
₩558.64
How sure are you?
38.7%

+ What do you gain per year?

Total Gains per Share
₩-265.67
Return On Investment
-16.3%

For what price can you sell your share?

Current Price per Share
₩1,632.00
Expected price per share
₩0 - ₩1,777
How sure are you?
50%

1. Valuation of Samsung Pharm (5 min.)




Live pricePrice per Share (EOD)

₩1,632.00

Intrinsic Value Per Share

₩-3,773.08 - ₩-4,458.07

Total Value Per Share

₩-2,948.77 - ₩-3,633.75

2. Growth of Samsung Pharm (5 min.)




Is Samsung Pharm growing?

Current yearPrevious yearGrowGrow %
How rich?$54.3m$80.3m-$16.7m-26.3%

How much money is Samsung Pharm making?

Current yearPrevious yearGrowGrow %
Making money-$4.3m-$4.3m$49.1k1.1%
Net Profit Margin-49.9%-48.8%--

How much money comes from the company's main activities?

3. Financial Health of Samsung Pharm (5 min.)




What can you expect buying and holding a share of Samsung Pharm? (5 min.)

Welcome investor! Samsung Pharm's management wants to use your money to grow the business. In return you get a share of Samsung Pharm.

What can you expect buying and holding a share of Samsung Pharm?

First you should know what it really means to hold a share of Samsung Pharm. And how you can make/lose money.

Speculation

The Price per Share of Samsung Pharm is ₩1,632. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Samsung Pharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Samsung Pharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩824.31. Based on the TTM, the Book Value Change Per Share is ₩-66.42 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-65.56 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Samsung Pharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.090.0%-0.050.0%-0.050.0%-0.050.0%-0.040.0%
Usd Book Value Change Per Share-0.090.0%-0.050.0%-0.050.0%-0.020.0%0.020.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.090.0%-0.050.0%-0.050.0%-0.020.0%0.020.0%
Usd Price Per Share1.52-1.85-2.30-2.77-2.87-
Price to Earnings Ratio-4.21--14.09--25.15--16,588,386.95--10,166,600.31-
Price-to-Total Gains Ratio-16.52--56.49--100.87--32.97--23.60-
Price to Book Ratio2.64-2.73-2.67-3.00-3.85-
Price-to-Total Gains Ratio-16.52--56.49--100.87--32.97--23.60-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.1424
Number of shares875
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.05-0.02
Usd Total Gains Per Share-0.05-0.02
Gains per Quarter (875 shares)-40.68-18.52
Gains per Year (875 shares)-162.73-74.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-163-1730-74-84
20-325-3360-148-158
30-488-4990-222-232
40-651-6620-296-306
50-814-8250-370-380
60-976-9880-445-454
70-1139-11510-519-528
80-1302-13140-593-602
90-1465-14770-667-676
100-1627-16400-741-750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.017.00.010.5%6.022.03.019.4%6.022.03.019.4%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%5.014.00.026.3%12.019.00.038.7%12.019.00.038.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.031.00.0%0.00.031.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%5.014.00.026.3%12.019.00.038.7%12.019.00.038.7%

Fundamentals of Samsung Pharm

About Samsung Pharm

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 11:49:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Samsung Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Samsung Pharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Samsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -101.2% means that ₩-1.01 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Samsung Pharm:

  • The MRQ is -101.2%. The company is making a huge loss. -2
  • The TTM is -49.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-101.2%TTM-49.9%-51.3%
TTM-49.9%YOY-48.8%-1.1%
TTM-49.9%5Y-61.2%+11.2%
5Y-61.2%10Y-42.9%-18.2%
1.1.2. Return on Assets

Shows how efficient Samsung Pharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Samsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -13.0% Return on Assets means that Samsung Pharm generated ₩-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Samsung Pharm:

  • The MRQ is -13.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.0%TTM-6.2%-6.8%
TTM-6.2%YOY-5.0%-1.2%
TTM-6.2%5Y-4.9%-1.2%
5Y-4.9%10Y-3.5%-1.4%
1.1.3. Return on Equity

Shows how efficient Samsung Pharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Samsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -15.7% Return on Equity means Samsung Pharm generated ₩-0.16 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Samsung Pharm:

  • The MRQ is -15.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.7%TTM-7.3%-8.4%
TTM-7.3%YOY-5.7%-1.6%
TTM-7.3%5Y-5.9%-1.4%
5Y-5.9%10Y-4.4%-1.5%

1.2. Operating Efficiency of Samsung Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Samsung Pharm is operating .

  • Measures how much profit Samsung Pharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Samsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Samsung Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-24.6%+24.6%
5Y-24.6%10Y-18.8%-5.8%
1.2.2. Operating Ratio

Measures how efficient Samsung Pharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.12 means that the operating costs are ₩2.12 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Samsung Pharm:

  • The MRQ is 2.116. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.913. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.116TTM1.913+0.203
TTM1.913YOY1.806+0.107
TTM1.9135Y1.966-0.053
5Y1.96610Y1.809+0.157

1.3. Liquidity of Samsung Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Samsung Pharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.30 means the company has ₩2.30 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Samsung Pharm:

  • The MRQ is 2.298. The company is able to pay all its short-term debts. +1
  • The TTM is 2.862. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.298TTM2.862-0.564
TTM2.862YOY5.995-3.133
TTM2.8625Y3.928-1.066
5Y3.92810Y2.930+0.998
1.3.2. Quick Ratio

Measures if Samsung Pharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Samsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.52 means the company can pay off ₩0.52 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Samsung Pharm:

  • The MRQ is 0.516. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.103. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.516TTM1.103-0.586
TTM1.103YOY2.380-1.277
TTM1.1035Y1.756-0.653
5Y1.75610Y1.321+0.435

1.4. Solvency of Samsung Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Samsung Pharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Samsung Pharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.17 means that Samsung Pharm assets are financed with 17.0% credit (debt) and the remaining percentage (100% - 17.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Samsung Pharm:

  • The MRQ is 0.170. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.148. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.170TTM0.148+0.022
TTM0.148YOY0.113+0.035
TTM0.1485Y0.159-0.011
5Y0.15910Y0.248-0.089
1.4.2. Debt to Equity Ratio

Measures if Samsung Pharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Samsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 20.5% means that company has ₩0.20 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Samsung Pharm:

  • The MRQ is 0.205. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.174. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.205TTM0.174+0.031
TTM0.174YOY0.128+0.047
TTM0.1745Y0.197-0.023
5Y0.19710Y0.400-0.203

2. Market Valuation of Samsung Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Samsung Pharm generates.

  • Above 15 is considered overpriced but always compare Samsung Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -4.21 means the investor is paying ₩-4.21 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Samsung Pharm:

  • The EOD is -3.158. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.208. Based on the earnings, the company is expensive. -2
  • The TTM is -14.090. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.158MRQ-4.208+1.051
MRQ-4.208TTM-14.090+9.882
TTM-14.090YOY-25.145+11.055
TTM-14.0905Y-16,588,386.952+16,588,372.862
5Y-16,588,386.95210Y-10,166,600.306-6,421,786.646
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Samsung Pharm:

  • The EOD is -5.672. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.560. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.664. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.672MRQ-7.560+1.887
MRQ-7.560TTM-7.664+0.104
TTM-7.664YOY-21.511+13.847
TTM-7.6645Y-31.307+23.643
5Y-31.30710Y-19.188-12.119
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Samsung Pharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.64 means the investor is paying ₩2.64 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Samsung Pharm:

  • The EOD is 1.980. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.639. Based on the equity, the company is underpriced. +1
  • The TTM is 2.732. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.980MRQ2.639-0.659
MRQ2.639TTM2.732-0.093
TTM2.732YOY2.668+0.063
TTM2.7325Y3.002-0.270
5Y3.00210Y3.852-0.850
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Samsung Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---131.650-66.419-50%-65.556-50%-30.240-77%26.591-595%
Book Value Per Share--824.313965.683-15%1219.531-32%1301.686-37%1180.403-30%
Current Ratio--2.2982.862-20%5.995-62%3.928-42%2.930-22%
Debt To Asset Ratio--0.1700.148+15%0.113+51%0.159+7%0.248-31%
Debt To Equity Ratio--0.2050.174+18%0.128+61%0.197+4%0.400-49%
Dividend Per Share----0%-0%-0%-0%
Eps---129.216-65.905-49%-66.651-48%-73.364-43%-51.887-60%
Free Cash Flow Per Share---71.929-107.408+49%-13.146-82%-44.041-39%-44.041-39%
Free Cash Flow To Equity Per Share---71.929-107.408+49%-13.146-82%-44.041-39%-44.041-39%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.871+15%
Intrinsic Value_10Y_max---4458.067--------
Intrinsic Value_10Y_min---3773.082--------
Intrinsic Value_1Y_max---236.475--------
Intrinsic Value_1Y_min---232.152--------
Intrinsic Value_3Y_max---870.749--------
Intrinsic Value_3Y_min---828.054--------
Intrinsic Value_5Y_max---1698.215--------
Intrinsic Value_5Y_min---1562.448--------
Market Cap153604336128.000-33%204711661200.000248359952180.000-18%308596946740.000-34%372964088850.526-45%385604837499.433-47%
Net Profit Margin---1.012-0.499-51%-0.488-52%-0.612-40%-0.429-58%
Operating Margin----0%-0%-0.2460%-0.1880%
Operating Ratio--2.1161.913+11%1.806+17%1.966+8%1.809+17%
Pb Ratio1.980-33%2.6392.732-3%2.668-1%3.002-12%3.852-32%
Pe Ratio-3.158+25%-4.208-14.090+235%-25.145+498%-16588386.952+394202993%-10166600.306+241596946%
Price Per Share1632.000-33%2175.0002638.750-18%3278.750-34%3962.632-45%4096.936-47%
Price To Free Cash Flow Ratio-5.672+25%-7.560-7.664+1%-21.511+185%-31.307+314%-19.188+154%
Price To Total Gains Ratio-12.396+25%-16.521-56.486+242%-100.871+511%-32.967+100%-23.597+43%
Quick Ratio--0.5161.103-53%2.380-78%1.756-71%1.321-61%
Return On Assets---0.130-0.062-53%-0.050-62%-0.049-62%-0.035-73%
Return On Equity---0.157-0.073-53%-0.057-64%-0.059-62%-0.044-72%
Total Gains Per Share---131.650-66.419-50%-65.556-50%-30.240-77%26.591-595%
Usd Book Value--54309182.57863623253.705-15%80347837.959-32%85760547.944-37%77769936.356-30%
Usd Book Value Change Per Share---0.092-0.046-50%-0.046-50%-0.021-77%0.019-595%
Usd Book Value Per Share--0.5770.676-15%0.854-32%0.911-37%0.826-30%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.090-0.046-49%-0.047-48%-0.051-43%-0.036-60%
Usd Free Cash Flow---4738988.296-7076490.852+49%-866093.764-82%-2443447.700-48%-1497596.977-68%
Usd Free Cash Flow Per Share---0.050-0.075+49%-0.009-82%-0.031-39%-0.031-39%
Usd Free Cash Flow To Equity Per Share---0.050-0.075+49%-0.009-82%-0.031-39%-0.031-39%
Usd Market Cap107523035.290-33%143298162.840173851966.526-18%216017862.718-34%261074862.195-45%269923386.250-47%
Usd Price Per Share1.142-33%1.5231.847-18%2.295-34%2.774-45%2.868-47%
Usd Profit---8513271.851-4342103.806-49%-4391280.500-48%-4840527.036-43%-3423119.478-60%
Usd Revenue--8414214.4039092131.643-7%9070640.924-7%9282683.120-9%8774502.029-4%
Usd Total Gains Per Share---0.092-0.046-50%-0.046-50%-0.021-77%0.019-595%
 EOD+3 -5MRQTTM+8 -24YOY+3 -295Y+3 -2910Y+6 -27

3.2. Fundamental Score

Let's check the fundamental score of Samsung Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.158
Price to Book Ratio (EOD)Between0-11.980
Net Profit Margin (MRQ)Greater than0-1.012
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.516
Current Ratio (MRQ)Greater than12.298
Debt to Asset Ratio (MRQ)Less than10.170
Debt to Equity Ratio (MRQ)Less than10.205
Return on Equity (MRQ)Greater than0.15-0.157
Return on Assets (MRQ)Greater than0.05-0.130
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Samsung Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.754
Ma 20Greater thanMa 501,760.350
Ma 50Greater thanMa 1001,888.260
Ma 100Greater thanMa 2002,062.637
OpenGreater thanClose1,600.000
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets93,479,032
Total Liabilities15,894,485
Total Stockholder Equity77,584,547
 As reported
Total Liabilities 15,894,485
Total Stockholder Equity+ 77,584,547
Total Assets = 93,479,032

Assets

Total Assets93,479,032
Total Current Assets29,453,670
Long-term Assets64,025,362
Total Current Assets
Cash And Cash Equivalents 4,281,308
Net Receivables 6,620,083
Inventory 16,258,685
Other Current Assets 0
Total Current Assets  (as reported)29,453,670
Total Current Assets  (calculated)27,160,076
+/- 2,293,594
Long-term Assets
Property Plant Equipment 26,152,047
Intangible Assets 5,645,028
Long-term Assets  (as reported)64,025,362
Long-term Assets  (calculated)31,797,075
+/- 32,228,286

Liabilities & Shareholders' Equity

Total Current Liabilities12,818,347
Long-term Liabilities3,076,138
Total Stockholder Equity77,584,547
Total Current Liabilities
Accounts payable 5,858,692
Other Current Liabilities 0
Total Current Liabilities  (as reported)12,818,347
Total Current Liabilities  (calculated)5,858,692
+/- 6,959,655
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt595,486
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)3,076,138
Long-term Liabilities  (calculated)595,486
+/- 2,480,652
Total Stockholder Equity
Total Stockholder Equity (as reported)77,584,547
Total Stockholder Equity (calculated)0
+/- 77,584,547
Other
Capital Stock33,581,040
Common Stock Shares Outstanding 74,393
Net Invested Capital 77,584,547
Net Working Capital 16,635,323
Property Plant and Equipment Gross 41,631,105



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
> Total Assets 
133,304,609
125,175,408
162,451,593
138,284,747
136,136,892
142,667,638
140,651,803
154,194,193
158,903,221
169,219,398
169,805,305
160,646,664
165,868,707
165,197,880
158,650,919
184,974,872
181,808,336
180,739,516
178,725,958
165,773,084
162,646,487
155,196,226
145,456,078
137,810,944
132,371,440
128,954,739
117,914,809
117,154,869
112,342,202
103,439,097
93,479,032
93,479,032103,439,097112,342,202117,154,869117,914,809128,954,739132,371,440137,810,944145,456,078155,196,226162,646,487165,773,084178,725,958180,739,516181,808,336184,974,872158,650,919165,197,880165,868,707160,646,664169,805,305169,219,398158,903,221154,194,193140,651,803142,667,638136,136,892138,284,747162,451,593125,175,408133,304,609
   > Total Current Assets 
0
0
0
47,711,453
44,792,262
45,830,319
42,757,646
60,978,261
66,194,938
80,611,275
86,202,015
76,652,238
81,173,417
59,501,198
52,334,311
77,294,984
73,983,718
72,445,482
65,312,022
93,677,735
91,722,861
79,087,598
85,389,949
82,389,110
77,175,161
76,297,564
69,571,334
63,959,908
42,601,814
32,408,308
29,453,670
29,453,67032,408,30842,601,81463,959,90869,571,33476,297,56477,175,16182,389,11085,389,94979,087,59891,722,86193,677,73565,312,02272,445,48273,983,71877,294,98452,334,31159,501,19881,173,41776,652,23886,202,01580,611,27566,194,93860,978,26142,757,64645,830,31944,792,26247,711,453000
       Cash And Cash Equivalents 
0
0
0
5,390,180
1,859,919
3,640,897
2,054,144
2,931,620
2,559,689
14,785,064
10,943,995
3,151,358
11,936,664
3,104,041
2,057,253
28,926,683
31,399,008
22,612,115
26,444,834
57,413,223
53,687,548
11,577,186
26,097,439
30,208,384
31,449,375
59,352,449
35,986,098
26,963,129
11,212,012
1,881,807
4,281,308
4,281,3081,881,80711,212,01226,963,12935,986,09859,352,44931,449,37530,208,38426,097,43911,577,18653,687,54857,413,22326,444,83422,612,11531,399,00828,926,6832,057,2533,104,04111,936,6643,151,35810,943,99514,785,0642,559,6892,931,6202,054,1443,640,8971,859,9195,390,180000
       Short-term Investments 
0
0
0
2,966,345
2,966,345
1,200,000
1,200,000
19,495,411
1,200,000
1,200,000
1,200,000
1,200,000
38,497,440
24,515,051
17,782,428
18,563,910
14,466,825
21,558,770
2,586,355
600,000
10,600,000
40,600,000
38,304,260
33,871,992
31,585,420
1,508,901
20,000,000
20,000,000
10,000,000
8,000,000
0
08,000,00010,000,00020,000,00020,000,0001,508,90131,585,42033,871,99238,304,26040,600,00010,600,000600,0002,586,35521,558,77014,466,82518,563,91017,782,42824,515,05138,497,4401,200,0001,200,0001,200,0001,200,00019,495,4111,200,0001,200,0002,966,3452,966,345000
       Net Receivables 
16,629,703
13,724,414
15,375,433
16,229,582
18,065,460
17,475,789
17,517,431
18,921,371
18,916,840
23,569,131
30,073,917
32,712,336
28,919,839
29,722,272
27,772,759
15,539,371
13,525,345
13,295,562
12,991,982
12,499,733
15,391,054
11,891,995
9,630,707
9,327,272
7,363,158
6,927,331
7,009,184
6,506,584
7,989,763
6,456,591
6,620,083
6,620,0836,456,5917,989,7636,506,5847,009,1846,927,3317,363,1589,327,2729,630,70711,891,99515,391,05412,499,73312,991,98213,295,56213,525,34515,539,37127,772,75929,722,27228,919,83932,712,33630,073,91723,569,13118,916,84018,921,37117,517,43117,475,78918,065,46016,229,58215,375,43313,724,41416,629,703
       Other Current Assets 
2,964,434
5,960,400
5,261,098
8,878,153
8,641,196
1,276,129
803,028
18,957,470
1,344,882
915,563
1,111,633
1,191,710
1,473,303
984,050
1,211,885
224,241
40,893
0
0
0
1
0
-1
1
0
0
-1
1
1
1
0
0111-1001-10100040,893224,2411,211,885984,0501,473,3031,191,7101,111,633915,5631,344,88218,957,470803,0281,276,1298,641,1968,878,1535,261,0985,960,4002,964,434
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
84,695,291
105,696,682
106,316,609
107,679,888
107,824,617
108,294,034
113,413,936
72,095,349
70,923,626
76,108,628
60,066,129
55,421,834
55,196,279
52,657,175
48,343,474
53,194,961
69,740,388
71,030,789
64,025,362
64,025,36271,030,78969,740,38853,194,96148,343,47452,657,17555,196,27955,421,83460,066,12976,108,62870,923,62672,095,349113,413,936108,294,034107,824,617107,679,888106,316,609105,696,68284,695,291000000000000
       Property Plant Equipment 
44,754,549
53,634,020
59,305,759
72,405,351
72,861,488
76,011,790
75,351,213
75,038,445
74,233,445
73,593,418
73,839,267
73,435,191
73,944,115
77,165,646
78,135,759
0
0
0
0
0
0
0
0
0
0
31,160,202
26,643,515
26,718,495
26,682,563
26,667,399
26,152,047
26,152,04726,667,39926,682,56326,718,49526,643,51531,160,202000000000078,135,75977,165,64673,944,11573,435,19173,839,26773,593,41874,233,44575,038,44575,351,21376,011,79072,861,48872,405,35159,305,75953,634,02044,754,549
       Goodwill 
2,712,305
2,712,305
2,712,305
1,437,394
1,437,394
1,437,394
1,437,394
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001,437,3941,437,3941,437,3941,437,3942,712,3052,712,3052,712,305
       Long Term Investments 
0
0
0
0
0
4,465,052
4,542,024
0
491,562
955,162
955,162
955,162
3,955,161
22,723,325
22,269,179
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000022,269,17922,723,3253,955,161955,162955,162955,162491,56204,542,0244,465,05200000
       Intangible Assets 
8,162,477
7,952,855
7,683,460
2,481,508
2,419,412
2,357,317
2,300,635
213,986
209,705
205,425
201,145
383,229
3,521,314
3,665,012
3,769,571
425,785
785,990
724,082
699,164
655,418
652,944
969,637
871,764
837,930
987,681
1,166,309
1,200,000
1,200,000
13,200,000
13,200,915
5,645,028
5,645,02813,200,91513,200,0001,200,0001,200,0001,166,309987,681837,930871,764969,637652,944655,418699,164724,082785,990425,7853,769,5713,665,0123,521,314383,229201,145205,425209,705213,9862,300,6352,357,3172,419,4122,481,5087,683,4607,952,8558,162,477
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
70,001
0
0
107,679,888
0
0
0
0
1
0
0
0
1
0
0
0
-1
0
-1
-10-1000100010000107,679,8880070,001000000000000
> Total Liabilities 
85,717,043
67,714,395
68,673,710
55,906,982
56,377,407
64,255,844
64,688,977
60,325,702
55,996,299
33,453,297
33,037,248
28,983,687
28,012,104
24,889,841
24,643,748
45,107,571
49,416,821
47,211,979
56,810,738
15,553,106
15,426,869
14,685,334
18,185,605
12,040,431
15,078,196
15,477,909
15,324,892
17,371,811
16,123,851
13,463,602
15,894,485
15,894,48513,463,60216,123,85117,371,81115,324,89215,477,90915,078,19612,040,43118,185,60514,685,33415,426,86915,553,10656,810,73847,211,97949,416,82145,107,57124,643,74824,889,84128,012,10428,983,68733,037,24833,453,29755,996,29960,325,70264,688,97764,255,84456,377,40755,906,98268,673,71067,714,39585,717,043
   > Total Current Liabilities 
31,042,122
46,702,566
47,556,955
36,507,884
45,492,719
54,037,701
55,522,510
52,178,175
47,857,436
25,433,709
24,869,048
24,693,164
23,935,616
22,199,734
22,032,456
41,894,382
41,576,577
39,195,850
50,190,419
13,650,934
14,647,120
13,761,862
16,697,166
10,465,288
13,488,560
13,879,865
14,233,036
16,573,332
15,467,545
12,770,769
12,818,347
12,818,34712,770,76915,467,54516,573,33214,233,03613,879,86513,488,56010,465,28816,697,16613,761,86214,647,12013,650,93450,190,41939,195,85041,576,57741,894,38222,032,45622,199,73423,935,61624,693,16424,869,04825,433,70947,857,43652,178,17555,522,51054,037,70145,492,71936,507,88447,556,95546,702,56631,042,122
       Short-term Debt 
0
0
0
44,183,567
43,118,954
51,730,458
19,278,772
12,380,656
957,960
957,960
1,037,790
2,747,960
15,019,965
13,083,366
12,680,926
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000012,680,92613,083,36615,019,9652,747,9601,037,790957,960957,96012,380,65619,278,77251,730,45843,118,95444,183,567000
       Short Long Term Debt 
0
0
0
44,183,567
43,118,954
51,730,458
19,278,772
12,380,656
957,960
957,960
1,037,790
2,747,960
15,019,965
13,083,366
12,680,926
30,867,616
24,228,965
22,597,504
23,147,815
1,180,125
246,048
1,044,544
266,314
276,981
288,748
300,645
312,543
0
0
0
0
0000312,543300,645288,748276,981266,3141,044,544246,0481,180,12523,147,81522,597,50424,228,96530,867,61612,680,92613,083,36615,019,9652,747,9601,037,790957,960957,96012,380,65619,278,77251,730,45843,118,95444,183,567000
       Accounts payable 
5,904,810
5,154,720
4,551,759
4,284,952
5,279,342
4,884,745
4,834,163
6,211,166
6,141,156
6,174,433
6,192,418
4,692,344
6,088,976
6,114,007
6,082,373
7,375,563
6,757,753
5,779,966
5,603,180
4,607,900
5,581,927
3,605,214
5,325,621
1,708,347
4,911,700
4,157,673
4,727,326
6,503,797
6,577,443
5,243,234
5,858,692
5,858,6925,243,2346,577,4436,503,7974,727,3264,157,6734,911,7001,708,3475,325,6213,605,2145,581,9274,607,9005,603,1805,779,9666,757,7537,375,5636,082,3736,114,0076,088,9764,692,3446,192,4186,174,4336,141,1566,211,1664,834,1634,884,7455,279,3424,284,9524,551,7595,154,7205,904,810
       Other Current Liabilities 
4,761,987
5,598,579
4,646,344
4,346,814
5,001,365
4,429,654
3,749,575
5,506,353
10,324,077
3,934,390
3,807,654
3,662,717
2,615,319
2,783,820
3,077,968
0
-1
-1
0
-1
0
1
0
1
0
0
-1
1
-1
1
0
01-11-1001010-10-1-103,077,9682,783,8202,615,3193,662,7173,807,6543,934,39010,324,0775,506,3533,749,5754,429,6545,001,3654,346,8144,646,3445,598,5794,761,987
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
4,076,488
2,690,107
2,611,292
3,213,188
7,840,244
8,016,129
6,620,318
1,902,172
779,748
923,472
1,488,438
1,575,143
1,589,635
1,598,044
1,091,856
798,479
656,307
692,833
3,076,138
3,076,138692,833656,307798,4791,091,8561,598,0441,589,6351,575,1431,488,438923,472779,7481,902,1726,620,3188,016,1297,840,2443,213,1882,611,2922,690,1074,076,488000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
-44,183,567
-43,118,954
-51,730,458
-19,278,772
-12,380,656
-957,960
-957,960
-1,037,790
-2,747,960
-14,617,242
-12,726,955
-12,499,662
251,992
247,111
195,229
220,737
211,338
202,046
159,473
1,853,681
1,824,171
1,705,843
1,572,387
1,687,616
1,513,605
1,348,828
1,171,741
595,486
595,4861,171,7411,348,8281,513,6051,687,6161,572,3871,705,8431,824,1711,853,681159,473202,046211,338220,737195,229247,111251,992-12,499,662-12,726,955-14,617,242-2,747,960-1,037,790-957,960-957,960-12,380,656-19,278,772-51,730,458-43,118,954-44,183,567000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
92,139
0
0
0
0
0
0
0
0
-1
0
0
1
0
0
0
000100-10000000092,1390-10000000000000
       Deferred Long Term Liability 
0
0
0
1,700,980
2,023,445
2,223,361
2,513,220
1,955,674
2,242,996
2,408,762
2,609,585
2,846,065
3,146,064
3,299,891
3,414,203
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000003,414,2033,299,8913,146,0642,846,0652,609,5852,408,7622,242,9961,955,6742,513,2202,223,3612,023,4451,700,980000
> Total Stockholder Equity
47,587,563
57,461,010
93,777,880
82,377,764
79,759,485
78,411,794
75,962,825
93,868,491
102,906,922
135,766,101
136,768,057
131,662,977
137,856,603
140,308,039
134,007,171
139,867,301
132,391,515
133,527,537
121,915,220
150,219,978
147,219,619
140,510,892
127,270,474
125,770,512
117,293,244
113,476,830
102,589,917
99,783,058
96,218,351
89,975,495
77,584,547
77,584,54789,975,49596,218,35199,783,058102,589,917113,476,830117,293,244125,770,512127,270,474140,510,892147,219,619150,219,978121,915,220133,527,537132,391,515139,867,301134,007,171140,308,039137,856,603131,662,977136,768,057135,766,101102,906,92293,868,49175,962,82578,411,79479,759,48582,377,76493,777,88057,461,01047,587,563
   Common Stock
14,341,913
15,356,785
19,856,785
19,856,785
19,856,785
19,856,785
19,856,785
20,713,441
22,067,872
29,067,872
29,117,524
29,117,524
29,305,564
29,305,564
29,305,564
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000029,305,56429,305,56429,305,56429,117,52429,117,52429,067,87222,067,87220,713,44119,856,78519,856,78519,856,78519,856,78519,856,78515,356,78514,341,913
   Retained Earnings Total Equity0000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000
   Treasury Stock00000000000000000000-154,035-154,035-154,035-154,032-154,035-154,035-154,035-154,035-154,035-154,035-154,035
   Other Stockholders Equity 
0
0
0
11,739,145
11,653,485
11,840,535
12,713,443
23,808,958
23,808,960
23,773,759
24,610,931
23,773,760
23,773,760
26,227,949
26,083,539
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000026,083,53926,227,94923,773,76023,773,76024,610,93123,773,75923,808,96023,808,95812,713,44311,840,53511,653,48511,739,145000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue51,955,038
Cost of Revenue-28,981,967
Gross Profit22,973,07122,973,071
 
Operating Income (+$)
Gross Profit22,973,071
Operating Expense-69,992,108
Operating Income-18,037,070-47,019,037
 
Operating Expense (+$)
Research Development2,279,208
Selling General Administrative33,328,154
Selling And Marketing Expenses-
Operating Expense69,992,10835,607,362
 
Net Interest Income (+$)
Interest Income806,678
Interest Expense-73,369
Other Finance Cost-0
Net Interest Income733,309
 
Pretax Income (+$)
Operating Income-18,037,070
Net Interest Income733,309
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-23,674,917-18,037,070
EBIT - interestExpense = -73,369
-24,812,022
-24,738,653
Interest Expense73,369
Earnings Before Interest and Taxes (EBIT)--23,601,548
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-23,674,917
Tax Provision-1,137,105
Net Income From Continuing Ops-24,812,022-24,812,022
Net Income-24,812,022
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--733,309
 

Technical Analysis of Samsung Pharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Samsung Pharm. The general trend of Samsung Pharm is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Samsung Pharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Samsung Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,725 < 1,777 < 1,777.

The bearish price targets are: .

Tweet this
Samsung Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Samsung Pharm. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Samsung Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Samsung Pharm. The current macd is -75.04962757.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Samsung Pharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Samsung Pharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Samsung Pharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Samsung Pharm Daily Moving Average Convergence/Divergence (MACD) ChartSamsung Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Samsung Pharm. The current adx is 17.67.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Samsung Pharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Samsung Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Samsung Pharm. The current sar is 1,797.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Samsung Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Samsung Pharm. The current rsi is 29.75. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
Samsung Pharm Daily Relative Strength Index (RSI) ChartSamsung Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Samsung Pharm. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Samsung Pharm price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Samsung Pharm Daily Stochastic Oscillator ChartSamsung Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Samsung Pharm. The current cci is -122.24132989.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Samsung Pharm Daily Commodity Channel Index (CCI) ChartSamsung Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Samsung Pharm. The current cmo is -45.43609465.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Samsung Pharm Daily Chande Momentum Oscillator (CMO) ChartSamsung Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Samsung Pharm. The current willr is -84.77366255.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Samsung Pharm Daily Williams %R ChartSamsung Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Samsung Pharm.

Samsung Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Samsung Pharm. The current atr is 50.52.

Samsung Pharm Daily Average True Range (ATR) ChartSamsung Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Samsung Pharm. The current obv is 54,430,942.

Samsung Pharm Daily On-Balance Volume (OBV) ChartSamsung Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Samsung Pharm. The current mfi is 23.21.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Samsung Pharm Daily Money Flow Index (MFI) ChartSamsung Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Samsung Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Samsung Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Samsung Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.754
Ma 20Greater thanMa 501,760.350
Ma 50Greater thanMa 1001,888.260
Ma 100Greater thanMa 2002,062.637
OpenGreater thanClose1,600.000
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Samsung Pharm with someone you think should read this too:
  • Are you bullish or bearish on Samsung Pharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Samsung Pharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Samsung Pharm

I send you an email if I find something interesting about Samsung Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Samsung Pharm.

Receive notifications about Samsung Pharm in your mailbox!